Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement

Banach, Maciej; Štulc, Tomáš; Dent, Ricardo; Tóth, Peter P.

doi:10.1016/j.ijcard.2016.09.075

Cited by 161 publications

(141 citation statements)

References 148 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…Poor adherence to medication accounts for worsening of disease, death, and increased health care costs. However, previous reports suggest that 40-75% of patients discontinued their statin therapy within one year after initiation, with the greatest drop occurring in the first 6 months of treatment [20,21]. This is a matter of concern for both healthcare providers and patients because the first 6 months after stroke is the vulnerable period for recurrent CV events and statin discontinuation.…”

Section: Discussionmentioning

confidence: 99%

Medication Adherence of Statin Users after Acute Ischemic Stroke

et al. 2018

View full text Add to dashboard Cite

Although statins are established therapy for the secondary prevention of ischemic stroke, factors associated with adherence to statin treatment following ischemic stroke are not well known. To address this, we assessed the 6-month statin adherence using 8-item Morisky Medication Adherence Scale-8 in patients with acute ischemic stroke. Of 991 patients, 65.6% were adherent to statin at 6-month after discharge. Multiple logistic regression analysis showed that patients’ awareness of hyperlipidemia (OR 1.62; 95% CI 1.07–2.43), large artery stroke subtype (versus non-large artery stroke, OR 1.79; 95% CI 1.19–2.68), and alcohol drinking habits (OR 1.64; 95% CI 1.06–2.53) were positively associated, while high statin dose (versus low dose, OR 0.6; 95% CI 0.40–0.90) and higher daily number of medication pills (OR 0.93; 95% CI 0.88–0.97) were found to have a negative association with self-reported good adherence to statin medication after acute ischemic stroke. However, stroke severity and diagnosis of hyperlipidemia were not associated with adherence. These results suggest that educational and motivational interventions may enhance statin adherence because modifiable factors were associated with statin adherence.

show abstract

Section: Discussionmentioning

confidence: 99%

Medication Adherence of Statin Users after Acute Ischemic Stroke

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Statin intolerance is a phenomenon which has been observed for many years, however it has lately become a focus of interest due to the introduction of new drugs for combined therapy (primarily ezetimibe and PCSK9 inhibitors but also ETC-1002) and studies investigating the inefficacy of statin treatment with an emphasis on statin nonresponse, statin non-adherence, statin discontinuation or statin intolerance [4, 5, 155]. Statin intolerance should be defined as the lack of possibility to use a statin therapy – both with respect to a statin drug and its dose – that would be appropriate for the existing cardiovascular risk [5, 32].…”

Section: Adverse Effects Associated With Dyslipidaemia Treatment/mentioning

confidence: 99%

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016

Banach¹,

Jankowski²,

Jóźwiak³

et al. 2017

aoms

Self Cite

145

View full text Add to dashboard Cite

“…However, these therapies are either in development or have been terminated for reasons such as safety and efficacy. New therapies for reducing Lp(a) are expected to be introduced in the near future, such as antisense therapy, which targets apo(a), and next-generation PCSK9 inhibitors (34)(35)(36)(37)(38). We think that these therapies will provide more information elucidating the Lp(a) metabolism and the clinical value of Lp(a) reduction.…”

Section: Perspectivesmentioning

confidence: 99%

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9

Kotani

Banach

2017

J. Thorac. Dis.

Self Cite

View full text Add to dashboard Cite

Lipoprotein(a) [Lp(a)] has been identified as a risk factor for cardiovascular disease. Lp(a) levels are also high under certain clinical conditions, including familial hypercholesterolemia and high blood lowdensity lipoprotein (LDL) cholesterol levels. Few effective generic therapies for modulating Lp(a) have been developed. However, new therapies involving inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) using monoclonal antibodies have markedly reduced the blood LDL levels-and the Lp(a) levels as well. Much attention has therefore been focused on this therapy and its utility. The mechanism by which PCSK9 inhibitors reduce the Lp(a) levels remains unclear. We here describe the effects of PCSK9 inhibitors on Lp(a) and discuss potential mechanisms and perspectives of this topic.

show abstract

Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement

Cited by 161 publications

References 148 publications

Medication Adherence of Statin Users after Acute Ischemic Stroke

Medication Adherence of Statin Users after Acute Ischemic Stroke

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9

Contact Info

Product

Resources

About